116 results about "Tumor cell membrane" patented technology

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

A method for preparing nanoparticles of triterpenoid small molecules co-assembled with Ce6 and copper ions wrapped in cancer cell membranes and its application. The present invention prepares a pure natural co-assembled nanotransmission system with new morphological characteristics and multiple biological activities - terpenoid compound and photosensitizer co-assembled nanoparticles. In the composite nanoassembly, triterpenoid compounds and photosensitizer Ce6 are assembled into nanoparticles, providing effective and safe chemotherapy and photodynamic therapy. Subsequently, Cu is complexed on the surface of the nanoparticles. 2+ , when Cu is introduced 2+ When activated, the reduced PDT effect caused by excessive glutathione in the tumor consuming reactive oxygen species can be counteracted. Furthermore, it can enhance CDT therapy through a Fenton-like catalytic reaction with overexpressed H₂O₂ at the tumor site. Finally, these molecules are encapsulated by the tumor cell membrane. By constructing CM@OABACe6 / CuNPs with homologous targeting, a triple synergistic platform for cancer treatment using PDT, chemotherapy, and CDT has been created.

The invention discloses a method for preparing a multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method, and relates to a preparation method of a nano-hydroxyapatite-based tumor vaccine. The invention aims to solve the problems of low antigen presentation efficiency of existing tumor vaccines and complex preparation process of nano vaccines based on tumor cell membranes. The preparation method comprises the following steps: 1, preparing small-particle-size calcium-based nanoparticles; and 2, synthesizing the HAP NV (at) DOX nano compound. The preparation method is used for preparing the multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method.

The present invention discloses a fluorescent probe and its preparation method and application. The structural formula of the fluorescent probe of the present invention is: ‑ Cl ‑ Br ‑ , I ‑ The fluorescent probe of the present invention can rapidly undergo a bioorthogonal shear reaction to specifically activate fluorescence at the tumor site, thereby improving the imaging specificity of the target site. Simultaneously, the bioorthogonal coupling group of the probe is used to undergo biocoupling with cells, allowing the probe to be anchored on tumor cell membrane glycoproteins for long-term fluorescence imaging. The probe is suitable for non-invasive detection of tumors and surgical resection of tumors.

The present invention belongs to the field of biological probe technology, and in particular relates to a small molecule probe HBAPE-Ac3ManNAz based on sugar metabolism labeling and its application in improving the targeting of platinum drugs. The present invention provides a small molecule probe HBAPE-Ac3ManNAz based on sugar metabolism labeling. The probe can selectively label tumor cells or tissues in vivo or in vitro as a metabolic precursor, and provide new targets for refractory tumors such as triple-negative breast cancer that lack specific targeting receptors; a pharmacodynamic molecule DBCO-PEG8-Oxp(IV) complex that reacts orthogonally with the probe is synthesized. The complex reacts with an azide tag marked on the tumor cell membrane through a bioorthogonal reaction, thereby improving the targeted transport ability of platinum drugs to tumors and reducing toxic side effects, providing a new theoretical basis for the targeted treatment of tumors in organisms.

The present application relates to a kind of chitosan derivatives, its preparation method and application, belong to biological medical polymer material technical field.The method includes under the action of first catalyst, N-(2-hydroxypropyl)-3-trimethylammonium chloride chitosan is dissolved in first solvent, second solvent containing n-hexanoic anhydride is added to the first solvent containing N-(2-hydroxypropyl)-3-trimethylammonium chloride chitosan and is reacted, obtains chitosan derivative.The preparation method of the present application is easy to obtain raw material, and reaction condition is mild;And the chitosan derivative obtained carries a large number of positive charge, can be combined to the surface of negative electric tumor cell membrane by electrostatic interaction, promotes the interaction between the hydrophobic part of chitosan derivative and cell membrane phospholipid hydrophobic chain, destroys cell membrane stability and finally causes membrane lysis to make tumor cell necrosis.

The invention relates to a polypeptide for targeted destruction of lipid droplets and application of the polypeptide in preparation of antitumor drugs, and belongs to the technical field of biological drug manufacturing. In order to solve the problem that an existing anti-tumor drug aiming at tumor lipid droplets cannot effectively inhibit immune escape of tumor cells while destroying the lipid droplets, the invention provides a polypeptide for targeted destruction of the lipid droplets, and the polypeptide comprises a PLIN2 targeted peptide fragment, a self-assembly peptide fragment, an enzyme response peptide fragment and an HLA-E targeted peptide fragment which are connected in sequence. On the basis of a double-targeting strategy, the polypeptide for targeted destruction of the lipid droplets is constructed, and the polypeptide can target the PLIN2 protein on the surfaces of the lipid droplets; the self-assembled peptide fragment can form a nanofiber structure on the surface of the lipid droplet, the structure and function of the lipid droplet are destroyed, endoplasmic reticulum stress is caused, and tumor cell immunogenicity death is caused. The HLA-E targeting peptide fragment released by polypeptide digestion can specifically target HLA-E on a tumor cell membrane, block an NKG2A-HLA-E pathway, and effectively inhibit immune escape of tumor cells.

The application discloses a kind of for sensitizing lung cancer radiotherapy biomimetic nano delivery system and preparation method and application, it belongs to the field of biological medicine, wherein, biomimetic nano delivery system is core-shell structure, including core and the shell of the core outer layer being wrapped;Wherein, core is the lipid nanoparticle of therapeutic nucleic acid being loaded;Shell is tumor cell membrane vesicle;Therapeutic nucleic acid is the short hairpin RNA expression plasmid of targeted deubiquitinating enzyme CYLD gene.The application solves lung cancer radiotherapy resistance problem from mechanism, by therapeutic nucleic acid specific knockdown deubiquitinating enzyme CYLD gene, effectively blocks CYLD / NRP1 signal shaft, to reverse the metabolic reprogramming of tumor cell, significantly enhance its radiotherapy sensitivity, realize to the low-toxicity treatment of radiation resistance lung cancer.

The invention discloses a nuclide labeled cell membrane coated nano material as well as a preparation method and application thereof. The nuclide-labeled cell membrane-coated nano material is obtained by loading beta nuclide on a manganese-based monatomic nano enzyme coated with a tumor cell membrane, and the manganese-based monatomic nano enzyme has hollow mesopores. The invention also discloses an application of the nuclide labeled cell membrane coated nano material in preparation of a drug targeting carrier or a tumor treatment drug. The nuclide-labeled cell membrane-coated nano-material can be efficiently targeted to a tumor site, has self-cascade catalytic enzyme-like activity, and can effectively exert an anti-tumor effect.

The invention discloses a fusion membrane packaged gold-iron core-shell nano diagnosis and treatment preparation as well as a preparation method and application thereof. The preparation takes gold-iron core-shell nanoparticles as a core, and the surface of the gold-iron core-shell nanoparticles is coated with a biomimetic membrane formed by fusion of bacterial outer membrane vesicles and tumor cell membranes. The preparation method comprises the steps of synthesis of the gold-iron nano core, surface functionalization and self-assembly coating of the fusion membrane. The preparation can simultaneously exert photothermal therapy and ferroptosis induction effects under near-infrared light irradiation, effectively initiates tumor cell immunogenicity death, and cooperatively activates dendritic cells and enhances T cell immune response by means of a pathogen related molecular mode carried by the fusion membrane and a tumor related antigen. Experiments show that the preparation can significantly inhibit tumor growth and metastasis, induce long-acting anti-tumor immune memory, and provide a multi-mode synergistic nano platform for tumor immunotherapy.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

The invention discloses a bionic hybrid nano regulator for enhancing cell copper death and a preparation method and application thereof, and belongs to the technical field of biomedical materials. The invention designs a bionic nano-platform which simultaneously loads a lactic acid regulator cyclostilbene Su 3118 and a copper ion carrier disulfiram DSF, and the bionic nano-platform is combined with hybrid macrophages and tumor cell membranes to construct a nano-regulator SCTDM. The nano regulator can exert multiple functions, including tumor targeting, in-situ photothermal therapy, lactic acid regulation and enhanced copper death. The nano regulator provided by the invention is simple and convenient to manufacture, is combined with in-situ photothermal therapy and lactic acid regulation and is used for enhancing cell death immunotherapy of copper death so as to eliminate primary tumors and delay relapse, and a technical support is provided for regulating immunity by enhancing copper-induced cell death through metabolic reprogramming.

An anti-tumor pharmaceutical composition based on immune checkpoint blocking and a use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride and a T cell enhancer, the T cell enhancer being at least one of vitamin E and thymosin. By means of a series of in vivo and in vitro experiments, it was found for the first time that cannabidiol and paroxetine hydrochloride can effectively reduce the expression of PD-L1 on a tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the effect of T cells in killing tumor cells. T cell enhancer added on this basis can further increase the number and activity of T cells and significantly enhance the killing ability of T cells after relief from immunosuppression, greatly improving the anti-tumor effect of a drug. The components cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin of the pharmaceutical composition can have a synergistic effect to improve the anti-tumor effect.

The invention discloses an anti-tumor pharmaceutical composition and application thereof, the pharmaceutical composition comprises cannabidiol and paroxetine hydrochloride, and the mass ratio of the cannabidiol to the paroxetine hydrochloride is (5: 1)-(20: 1). Research finds that cannabidiol and paroxetine hydrochloride can respectively reduce expression of PD-L1 on a tumor cell membrane through different mechanism ways, specifically, CBD promotes degradation of PD-L1 through a lysosome way; the PAR is used for promoting the degradation of the PD-L1 through a ubiquitin-proteasome way. Based on the discovery, the CBD and the PAR are further combined for use, and the result shows that compared with independent use of the CBD and the PAR, the combined use of the CBD and the PAR can play a synergistic anti-tumor role, and the CBD and the PAR have no obvious toxic and side effects and are relatively high in use safety.

The invention relates to the technical field of anti-tumor bionic nanomaterials, and discloses a preparation method and application of tumor-bacterial membrane chimeric nanoparticles, and the preparation method comprises the following steps: carrying out rotary evaporation on dimyristoyl phosphatidylcholine and cholesterol oleate to obtain an HDL rotary evaporation film; mixing the tumor cell membrane with the bacterial membrane to obtain a tumor-bacterial mixed membrane; pre-mixing apolipoprotein ApoA-1 with the tumor-bacteria mixed membrane, and adding the mixed solution into a container containing an HDL rotary evaporation membrane for hydration and reconstruction to obtain a crude suspension; and carrying out ultrafiltration purification on the crude suspension to obtain the tumor-bacterial membrane chimeric nanoparticles. The tumor cell membrane and the bacterial membrane are co-loaded on the high-density lipoprotein, so that the two membrane components can be co-delivered to the dendritic cells to induce maturation of the dendritic cells, are accumulated in tumors and drainage lymph nodes in vivo, activate CD8 + T cell response and have an inhibition effect on tumor growth.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

Disclosed herein is an anti-tumor pharmaceutical composition based on immune checkpoint blockade and use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride, and a T-cell enhancer, wherein the T-cell enhancer is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, cannabidiol and paroxetine hydrochloride were first found to be capable of effectively reducing the expression of PD-L1 on the tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the ability of T cells to kill tumor cells. The T-cell enhancer added on this basis can further increase the quantity and activity of T cells, significantly increase the killing ability of T cells after immunosuppression is relieved, and greatly improve the anti-tumor effect of the drug. The components of the pharmaceutical composition used in the present invention, namely, cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin, can exert a synergistic effect and improve the anti-tumor effect.

The invention discloses preparation and application of a biomimetic cell membrane modified photosensitizer. A tumor cell membrane bionic camouflage technology is adopted, the surface of the photosensitizer nanoparticle is coated with the tumor cell membrane through repeated membrane extrusion or ultrasound, the photosensitizer-coated tumor cell membrane bionic nanoparticle is prepared, the preparation process is simple, the cost is low, and a complex synthesis process is not needed. The bionic nanoparticle disclosed by the invention has the functions of homologous targeting and immune escape, and can realize near-infrared two-region imaging. In addition, the bionic nanoparticles can kill tumor cells through photo-thermal and photodynamic effects, and have the advantages of good curative effect and low toxic and side effects.

The embodiment of the invention discloses a method for screening a tumor immune checkpoint inhibitor based on electrochemical luminescence sensing. According to the invention, an electrochemiluminescence sensor is established, and resonance energy transfer between luminol (an electrochemiluminescence donor) and a PD-L1-targeting metal cluster (an electrochemiluminescence receptor) is utilized; the electrochemical luminescence sensor capable of rapidly, sensitively, simply, conveniently and quantitatively analyzing the equilibrium dissociation constant between the non-antibody immune checkpoint inhibitor and the PD-L1 expressed on the tumor cell membrane at low cost is established. The efficiency of blocking the PD-1 / PD-L1 by the inhibitor is evaluated through quantitative analysis of the constant, so that the potential non-antibody immune checkpoint inhibitor is effectively screened.

An anti-tumor pharmaceutical composition based on immune checkpoint blocking and a use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride and a T cell enhancer, the T cell enhancer being at least one of vitamin E and thymosin. By means of a series of in vivo and in vitro experiments, it was found for the first time that cannabidiol and paroxetine hydrochloride can effectively reduce the expression of PD-L1 on a tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the effect of T cells in killing tumor cells. T cell enhancer added on this basis can further increase the number and activity of T cells and significantly enhance the killing ability of T cells after relief from immunosuppression, greatly improving the anti-tumor effect of a drug. The components cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin of the pharmaceutical composition can have a synergistic effect to improve the anti-tumor effect.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The invention relates to a pyridazinic acid unit-containing cyclic ester peptide compound, a preparation method thereof, a pharmaceutical composition containing the compound, application of the compound in preparation of a medicine for inducing rupture and death of a tumor cell membrane, and application of the compound in preparation of a medicine for activating tumor immune response, and particularly relates to a pyridazinic acid unit-containing cyclic ester peptide compound and a pharmaceutical composition containing the pyridazinic acid unit-containing cyclic ester peptide compound. The invention also relates to application of the compound in preparation of medicines for treating diseases related to cell death in organisms.

The invention discloses an intelligent transdermal drug delivery system based on a tripterygium wilfordii exosome and a ferroptosis inducer as well as a preparation method and application of the intelligent transdermal drug delivery system, and belongs to the technical field of biological medicines. The method comprises the following steps: extracting tripterygium wilfordii exosomes (TExos) with natural anti-tumor activity, fusing the tripterygium wilfordii exosomes with a homologous tumor cell membrane by utilizing a repeated freeze-thaw method to construct a bionic targeting compound (CTE), and then loading RSL3 through a co-incubation method to form an R (at) CTE compound. The compound is further loaded into a porous microneedle through a 3D printing technology to prepare an R-(at) CTE-M transdermal drug delivery system. The drug delivery system constructed by the invention has excellent homologous targeting property and tumor penetrating ability, can effectively inhibit proliferation, migration and invasion of triple negative breast cancer cells, induce cell apoptosis and enhance cell ferroptosis, and shows a remarkable tumor inhibition effect and good biological safety in an animal model.

The invention provides a polypeptide or a pharmaceutically acceptable salt thereof and application of the polypeptide or the pharmaceutically acceptable salt in preparation of a tumor multidrug resistance reversal agent, and belongs to the technical field of biological medicines. The polypeptide can selectively act on tumor cells with negatively charged cell membranes through electrostatic interaction, has small influence on normal cells, and has good selectivity; meanwhile, a hydrophobic fragment in the structure is inserted into a tumor cell membrane phospholipid skeleton to destroy the integrity of a cell membrane, change the permeability of the cell membrane and inhibit the membrane protein function, so that more anti-tumor drug molecules can be promoted to enter tumor cells, the accumulation of the drug in the tumor cells is improved, the function of ABC transport protein on the membrane can be influenced, and the anti-tumor effect is improved. The excretion of intracellular drugs is inhibited, and finally, the aim of reversing the multidrug resistance of tumors is fulfilled. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used as a novel peptide tumor multidrug resistance reversal agent, can be potentially used in anti-tumor clinical treatment, and has a wide development prospect.

The invention relates to a genetically engineered bacterium and application thereof, a culture method of the genetically engineered bacterium and a pharmaceutical composition, and belongs to the technical field of tumor treatment. The invention provides a genetically engineered bacterium. The genetically engineered bacterium is composed of tumor vesicles and a thallus body, the tumor vesicles are connected with the thallus body through distearoyl phosphatidyl acetamide-N-polyethylene glycol 2000-hydroxysuccinimide, and the tumor vesicles are connected with the thallus body through distearoyl phosphatidyl acetamide- The thallus body comprises an overexpression vector of D-mannose isomerase; the engineering bacterium expresses D-mannose isomerase in an environment with oxygen volume concentration of 0-12%. The engineering bacterium of tumor microenvironment hypoxia induced mannose loaded with tumor cell membrane vesicles, constructed by the invention, can improve the in-vivo treatment effect of adoptive T cells.

The application discloses an antigen-engineered nanovesicle vaccine (AN-FV) and a preparation method and application thereof. The vaccine is formed by fusion of vesicles of tumor cell membranes obtained by pretreatment of functionalized nanometer preparations and vesicles of mature dendritic cell membranes; the functionalized nanometer preparations contain autophagy inhibiting siRNA and an immunogenicity enhancer, and can synergistically improve MHC-I expression of tumor cells and antigen immunogenicity. The vaccine of the application simultaneously presents high-density MHC-I-antigen peptide complexes and CD80 / CD86 costimulatory molecules on the surface of a single particle, simulates an immune synapse in a nanometer scale, and thus efficiently activates tumor-specific T cells. The vaccine integrates antigen source engineering, physiologicalization of costimulatory signals and nanometer platform integration, and provides a new scheme for overcoming the treatment bottleneck of immune "cold" tumors such as pancreatic cancer.

The invention discloses a method for overcoming tumor immune desert-type drug resistance by using a nano-carrier delivery vaccine. The method comprises the following steps: realizing targeted immune activation and microenvironment remodeling by constructing a three-stage structure collaborative delivery platform; the system comprises core-shell lipid nanoparticles (LNP) constructed based on a liposome self-assembly technology, mesoporous silica nanoparticles (MSNs) are adopted as a slow release module, and a manganese dioxide (MnO2) nano-cluster is anchored by a surface modified amino column [6] arene-lactose pyridine host-guest complex through a pi-pi accumulation effect; according to the present invention, through the dual targeting modification, the tumor cell membrane camouflage (retaining EGFR, CD44 and other membrane antigens) and the ApoA1 mimic peptide (22A peptide) synergistically act, the enrichment amount of the nanometer vaccine in the tumor tissue is 5.2 times of the normal liver tissue, and the problems that the traditional vaccine difficultly penetrates through the compact matrix of the immune desert type tumor and the lymph node activation efficiency is low are solved.

The invention belongs to the technical field of biomedical materials and tumor treatment, and discloses a biological orthogonal catalytic microneedle based on a cytotoxic polyethyleneimine matrix as well as a preparation method and application of the biological orthogonal catalytic microneedle. The microneedle patch comprises a backing layer and a microneedle array, wherein the microneedle array is formed by mixing polyvinyl alcohol (PVA) loaded with metal nanoparticles and polyethyleneimine (PEI) with a hydrogel matrix. According to the invention, the inherent cytotoxicity (membrane destroying ability) of PEI is creatively combined with the catalytic activity of a metal catalyst (such as palladium) to construct a synergistic treatment system which turns toxins into treasures. The PEI matrix has dual functions in the microneedle: on one hand, the PEI matrix is used as a potent ligand to anchor and stabilize the metal nanoparticles and prevent the metal nanoparticles from leaking; on the other hand, as a therapeutic agent, tumor cell membranes are destroyed through electrostatic interaction. The microneedle patch is activated by catalyzing a prodrug (such as doxorubicin protected by propargyloxycarbonyl) in situ, meanwhile, the physical membrane destruction effect of PEI is utilized, the synergistic anti-tumor effect of physical destruction and chemical killing is achieved, and the treatment efficiency of superficial tumors such as melanoma is remarkably improved.

The invention relates to a medicine for treating tumors, in particular to a tumor cell membrane and TKI co-modified sound-sensitive nano material, a preparation method thereof and application of the sound-sensitive nano material in the medicine for treating the tumors, and aims to solve the problems that in an existing thyroid cancer treatment method, the side effect is large when TKI is singly used; or the problem of insufficient curative effect caused by low bioavailability of the sound-sensitive material in SDT and poor aggregation of the tumor site is solved. The material comprises TKI, a sound-sensitive nano material body and a tumor cell membrane, the sound-sensitive nano material body is of a hollow structure; wherein one part of TKI is embedded in pores in the sound-sensitive nano material, and the other part of TKI is adsorbed on the outer surface of the sound-sensitive nano material body; the tumor cell membrane is coated on the outer surface of the sound-sensitive nano material body. The preparation method comprises the following steps: preparing FeTBP, preparing FeTBP loaded with TKI, and preparing a tumor cell membrane and TKI co-modified material FL (at) M. The invention also provides application of the material in medicines for treating tumors. The curative effect on thyroid tumor is improved.

The application relates to the technical field of magnetic particle imaging, and more particularly to an iron oxide nanoparticle and application of the iron oxide nanoparticle in magnetic particle imaging. The nanoparticle is an octahedral superparamagnetic ferroferric oxide nanoparticle, the nanoparticle is synthesized by adding a surfactant and controlling a reaction rate through a high-temperature thermal decomposition method, the surfactant includes oleic acid and oleylamine, the octahedral superparamagnetic ferroferric oxide nanoparticle is coated with an amphiphilic polymer, the amphiphilic polymer includes polymaleic anhydride-1-octadecenoic acid and polystyrene maleic anhydride copolymer, and the outer layer of the amphiphilic polymer includes biological membranes such as macrophage membranes, red blood cell membranes, neutrophil membranes and tumor cell membranes according to biological application requirements. The surface of the octahedral magnetic particle is a crystal face, the crystal face has low spin disorder and low anisotropy, so that the octahedral magnetic particle has the advantages of low coercivity and high initial magnetic susceptibility, and thus becomes a high-sensitivity magnetic particle imaging tracer.